China’s Specialty Pharma Supplier Delivers Domestic Alternative to Imported High-End Excipients with Global Compliance

Guangzhou, China – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients and APIs, today announced the launch of its USP-grade injectable soybean oil, a domestically manufactured alternative to imported products that addresses supply chain stability challenges for global pharmaceutical manufacturers. This product leverages the company’s proprietary green extraction technology, ensuring consistent quality and meeting stringent international standards. The USP-grade injectable soybean oil is now available for pre-order globally, with full-scale production scheduled to commence in June 2026.

Core Technology Breakthroughs and Product Highlights

Developed through the company’s national-level engineering research center, the USP-grade injectable soybean oil features three key advantages: First, it breaks long-term foreign market monopolization, raising the localization rate of high-end pharmaceutical lipid excipients from 10% to 90% in China. Second, it adopts the proprietary "supercritical CO₂ extraction-membrane separation-chromatography separation" integrated green technology, replacing traditional polluting processes to ensure environmental sustainability and product purity. Third, it provides stable supply capacity, eliminating the risks of import delays and price fluctuations faced by pharmaceutical manufacturers.

Global Compliance and Certifications

To meet global market access requirements, the USP-grade injectable soybean oil has obtained multiple international certifications, including US FDA US-DMF, EU CEP, Mexico Cofepris, and India DCGI. These certifications confirm that the product complies with regulatory standards in North America, Europe, Asia-Pacific, and other major regions, enabling its widespread use in high-end injectable formulations worldwide.

Availability and Customization Services

The USP-grade injectable soybean oil is now open for global pre-orders through Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.’s official website and authorized global distributors. In addition to standard products, the company offers customized processing services to meet the specific needs of pharmaceutical and special medical food manufacturers, including tailored purity levels and packaging specifications.

Authoritative Quotes

"The launch of our USP-grade injectable soybean oil marks a critical step in addressing the 'bottleneck' challenges in China’s high-end pharmaceutical excipient supply chain," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "This product not only provides a reliable domestic alternative for global clients but also demonstrates our commitment to advancing pharmaceutical self-reliance and ensuring supply chain security."

Industry Context and Corporate Strategy

According to Grand View Research, the global pharmaceutical excipients market reached $12.5 billion in 2025, driven by increasing demand for high-quality injectable formulations. Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.’s launch aligns with this market trend, positioning the company to expand its global footprint in the high-end pharmaceutical lipid segment.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to invest in R&D for pharmaceutical lipid technologies, with plans to launch additional high-end excipient products by the end of 2026. The company will also expand its global sales and service network to provide localized support for clients in more regions.

Company Profile

Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. was established in 1998 and is a core subsidiary of the Fortune Global 500 Guangzhou Pharmaceutical Group. As a national-level specialized, sophisticated, unique, and new "Little Giant" enterprise, it operates the only national engineering research center for traditional Chinese medicine process technology and new drug development. The company has over 240 patents, serves more than 1,000 clients worldwide, and its products are sold in over 20 countries and regions. Its mission is to achieve technological self-reliance, solve "bottleneck" problems, and protect pharmaceutical supply chain security. For more information, visit http://byshanhanfang.com/.

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All Rights Reserved.